NanoRepro AG (ETR:NN6)

Market Cap	19.74M +3.0%
Revenue (ttm)	4.34M -3.0%
Net Income	-1.99M
EPS	-0.16
Shares Out	12.61M
PE Ratio	n/a
Forward PE	n/a
Dividend	0.15 (9.59%)
Ex-Dividend Date	n/a

Volume	4,854
Open	1.600
Previous Close	1.600
Day's Range	1.565 - 1.600
52-Week Range	1.310 - 2.400
Beta	0.44
Analysts	Strong Buy
Price Target	4.48 (+185.94%)
Est. Earnings	Jun 7, 2027

About NanoRepro AG

NanoRepro AG engages in the development, manufacture, and distribution of rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. The company offers products in the areas of family planning, preventive healthcare, intolerances, and infectious diseases. It also develops and commercializes immunochromatographic lateral flow tests; and point of care testing for hospitals and medical practices. NanoRepro AG was incorporated in 2007 and is headquartered in Marburg, Germany.

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2007
• Employees: 22
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: NN6

Financial Performance

In 2025, NanoRepro AG's revenue was 4.34 million, a decrease of -3.02% compared to the previous year's 4.47 million. Losses were -1.99 million, -2.87% less than in 2024.

Analyst Summary

According to 2 analysts, the average rating for NN6 stock is "Strong Buy." The 12-month stock price target is €4.48, which is an increase of 185.94% from the latest price.

Price Target

€4.48

(185.94% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 26, 2026

Data Sources Report a data error